These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31670782)

  • 1. ARSA variants in α-synucleinopathies.
    Makarious MB; Diez-Fairen M; Krohn L; Blauwendraat C; Bandres-Ciga S; Ding J; Pihlstrøm L; Houlden H; Scholz SW; Gan-Or Z
    Brain; 2019 Dec; 142(12):e70. PubMed ID: 31670782
    [No Abstract]   [Full Text] [Related]  

  • 2. ARSA gene variants and Parkinson's disease.
    Fan Y; Mao CY; Dong YL; Shen S; Zhang QM; Yao DB; Liu F; Li MJ; Hu XC; Wang T; Liu YT; Liu H; Wang YL; Yuan YP; Zhang C; Yang J; Shi CH; Xu YM
    Brain; 2020 Jun; 143(6):e47. PubMed ID: 32437521
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply: ARSA gene variants and Parkinson's disease.
    Lee SJ; Lee JS; Funayama M; Yoo HS; Lee PH; Hattori N
    Brain; 2020 Jun; 143(6):e48. PubMed ID: 32437537
    [No Abstract]   [Full Text] [Related]  

  • 4. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.
    Lee JS; Kanai K; Suzuki M; Kim WS; Yoo HS; Fu Y; Kim DK; Jung BC; Choi M; Oh KW; Li Y; Nakatani M; Nakazato T; Sekimoto S; Funayama M; Yoshino H; Kubo SI; Nishioka K; Sakai R; Ueyama M; Mochizuki H; Lee HJ; Sardi SP; Halliday GM; Nagai Y; Lee PH; Hattori N; Lee SJ
    Brain; 2019 Sep; 142(9):2845-2859. PubMed ID: 31312839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving forward the in vivo diagnosis of the synucleinopathies.
    Vilas D
    Clin Auton Res; 2019 Dec; 29(6):575-576. PubMed ID: 30721384
    [No Abstract]   [Full Text] [Related]  

  • 6. Identifying the best biomarkers for α-synucleinopathies.
    Dauvilliers Y
    Lancet Neurol; 2021 Aug; 20(8):593-594. PubMed ID: 34302778
    [No Abstract]   [Full Text] [Related]  

  • 7. Skin α-synuclein differentiates synucleinopathies.
    Lemprière S
    Nat Rev Neurol; 2023 Mar; 19(3):129. PubMed ID: 36750670
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson's Disease.
    Doppler K
    J Parkinsons Dis; 2021; 11(3):937-947. PubMed ID: 33814464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The novel mechanism of α-synuclein propagation in synucleinopathy].
    Kawahata I
    Nihon Yakurigaku Zasshi; 2021; 156(4):251. PubMed ID: 34193707
    [No Abstract]   [Full Text] [Related]  

  • 11. In Vivo Detection of Underlying Synucleinopathies: Are We There Yet?
    Irwin D; Saint-Hilaire M
    Neurology; 2021 May; 96(20):925-926. PubMed ID: 33858996
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
    Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
    Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies.
    Sandoval IM; Marmion DJ; Meyers KT; Manfredsson FP
    J Parkinsons Dis; 2021; 11(s2):S189-S197. PubMed ID: 34092656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.
    Irwin DJ; Grossman M; Weintraub D; Hurtig HI; Duda JE; Xie SX; Lee EB; Van Deerlin VM; Lopez OL; Kofler JK; Nelson PT; Jicha GA; Woltjer R; Quinn JF; Kaye J; Leverenz JB; Tsuang D; Longfellow K; Yearout D; Kukull W; Keene CD; Montine TJ; Zabetian CP; Trojanowski JQ
    Lancet Neurol; 2017 Jan; 16(1):55-65. PubMed ID: 27979356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies.
    Brás IC; Outeiro TF
    Cells; 2021 Feb; 10(2):. PubMed ID: 33673034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Passive Immunotherapies for Synucleinopathies.
    Bergström AL; Kallunki P; Fog K
    Mov Disord; 2016 Feb; 31(2):203-13. PubMed ID: 26704735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modelling synucleinopathies in genetically modified animals--successes and failures].
    Ninkina NN; Ustiugov AA; Bukhman VL
    Mol Biol (Mosk); 2008; 42(5):840-55. PubMed ID: 18988533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural variants in SNCA gene and the implication to synucleinopathies.
    Chiba-Falek O
    Curr Opin Genet Dev; 2017 Jun; 44():110-116. PubMed ID: 28319736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.